Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Omnicell (OMCL) stock in plain English

Free brief · no signupStart here
OMCLPublished Nov 14, 2026
Omnicell Inc
Healthcare · Health Information Services
Manufactures automated dispensing cabinets and robotic systems that store, package, and track hospital medications.
Assets:
Titan XT hardwareNext-generation automated medication dispensing cabinets installed in clinical departments.
OmniSphere platformCloud-native software coordinating pharmacy operations, inventory tracking, and supply data.
XR2 robotic systemCentral pharmacy robotics that handle bulk medication storage, sorting, and barcoding.
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

69
OPS ScoreOperating finances
Latest quote
-4.27%$33.18
$1.53B
34.4×
$1.24B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 14, 2026Quotes updated Nov 20, 04:00 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was OMCL. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Omnicell (OMCL) do?

Omnicell Inc (OMCL) is a U.S.-listed company in Healthcare (Health Information Services). What it does: Manufactures automated dispensing cabinets and robotic systems that store, package, and track hospital medications. Integrates robotic medication dispensing cabinets with cloud inventory software inside hospital pharmacy networks. It is worth $1.53B on the market and sold $1.24B over the last year.

Market cap
$1.53B
P/E ratio
34.4×
Annual sales
$1.24B
Sector
Healthcare
Industry
Health Information Services
Brief updated
Nov 14, 2026

Brands and businesses behind OMCL

  • Titan XT: Automated medication dispensing cabinets sold directly to hospitals with ongoing maintenance and software subscriptions.
  • OmniSphere: Cloud software suite that earns recurring subscription fees by analyzing medication inventory across hospital networks.
  • XR2: Central pharmacy robotic system that generates revenue through large equipment sales and long-term service agreements.
  • EnlivenHealth: Digital patient engagement software that earns recurring software fees from retail pharmacies.
  • SureMed: Blister packaging cards sold to retail and institutional pharmacies for medication adherence programs.

OMCL’s flags, in plain English

Each flag is a number from Omnicell’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 14, 2026.

Low debt

Low debt, only 15% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Earnings Jumping

Profits up 53.3% this year. Profit per share is growing fast this year. One year does not make a trend, so check whether sales grew too.

Cheap on Cash Flow

Priced at 10.7 times the cash it generates each year. The share price is low compared with the cash the business actually brings in, and cash is harder to dress up than profit.

Priced for Perfection

Priced at 34.4 times its yearly profit, so a lot of growth is already expected. The share price already assumes strong results, so news that is merely good can still send it down.

2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.

Questions about OMCL

How big is Omnicell?

Omnicell’s market cap is $1.53B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $1.24B: what customers paid the company over the last year, before any costs.

What is OMCL’s P/E ratio?

OMCL’s P/E ratio is 34.4×. Investors pay about 34.4 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with OMCL?

Tight hospital capital budgets and elevated borrowing costs cause healthcare systems to delay multi-year equipment purchases. That is one risk on Omnicell’s card. Its first risk flag is Priced for Perfection, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Omnicell’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. OMCL’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card